Tamoxifen Metabolism in Breast Cancer Patients
Author Information
Author(s): M.C. Etienne, G. Milano, J.L. Fischell, M. Frenay, E. Fransois, J.L. Formentol, J. Gioanni, M. Namer
Primary Institution: Centre Antoine Lacassagne
Hypothesis
What is the metabolic profile of tamoxifen and its metabolites in breast cancer patients?
Conclusion
Tamoxifen and its metabolites have varying effects on breast cancer cells, with their activity dependent on concentration and receptor status.
Supporting Evidence
- Tamoxifen and its metabolites were measured in blood at the time of first drug intake and at steady state.
- Demethylation was identified as the major metabolic pathway for tamoxifen.
- 4-Hydroxytamoxifen was found to be the most active metabolite against breast cancer cells.
Takeaway
Tamoxifen is a medicine for breast cancer that changes in the body, and how it works can depend on how much is in the blood and the type of cancer.
Methodology
The study involved pharmacokinetic analysis of tamoxifen and its metabolites in blood samples from 81 breast cancer patients, along with in vitro testing on breast cancer cell lines.
Limitations
The study had a limited number of evaluable patients for treatment response analysis, and the variability in metabolite production among patients was significant.
Participant Demographics
Mean age of participants was 65.6 years, with advanced breast cancer and no active liver disease.
Want to read the original?
Access the complete publication on the publisher's website